HardEndocrinologyType 2 diabetes with CVD and CKDau-amcau-racp
A 60-year-old man with type 2 diabetes and established coronary artery disease has an HbA1c of 64 mmol/mol (8.0%) on metformin alone. eGFR is 55 mL/min/1.73 m² and he has albuminuria. According to Australian diabetes guidelines, which additional glucose-lowering agent is preferred to improve both glycaemic control and cardiovascular/renal outcomes?